All News
Filter News
Found 3,195 articles
-
Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference
10/17/2019
POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright 3rd Annual NASH Investor Conference and the Company will provide an overview of its two clinical stage candidates, PXL770,
-
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
10/17/2019
Rafael will provide the compound for the study.
-
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
10/17/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from the open-label extension portion of the Phase 2/3 TAZPOWER study evaluating elamipretide in patients with Barth syndrome
-
Auburn University's new mobile lab expands research opportunities far and wide
10/17/2019
A bird can migrate hundreds of miles in a day unimpeded, but an average human can run for just 30 minutes and feel exhausted.
-
Twist Bioscience Showcases Next-Generation Sequencing Products and Results at American Society for Human Genetics 2019 Annual Meeting
10/16/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer, company and collaborator data using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS).
-
Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.
-
Reproductive Medicine Associates of New York Presents Innovative Research at ASRM's 75th Annual Meeting
10/15/2019
Members of Manhattan-based fertility center Reproductive Medicine Associates of New York (RMA of New York) presented 31 scientific abstracts at the 75th annual meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia, Pennsylvania
-
CohBar to Present at the 2019 BIO Investor Forum
10/15/2019
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present at the 2019 BIO Investor Forum, which is being held October 22-23 at the Westin St. Francis Hotel in San Francisco, CA.
-
Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
10/14/2019
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT
-
Cerecor To Sell Pediatric Portfolio to AYTU BioScience
10/14/2019
Cerecor Inc. announced that it has entered into an asset purchase agreement with AYTU BioScience, Inc. to sell Cerecor’s Pediatric Portfolio in a deal valued in excess of $32 million.
-
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019
10/11/2019
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting being held from November 5 – 10, at the Walter E. Washington Convention Center in Washington, D.C.
-
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
10/10/2019
Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license
-
Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators
10/10/2019
Reata Pharmaceuticals, Inc. announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie, Inc.
-
GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy
10/9/2019
First study to find direct evidence that therapeutic gene is transferred from the injected eye to the uninjected contralateral eye of primates
-
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
10/8/2019
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
-
Allegro Ophthalmics to Present Clinical Research on the Company’s Novel Integrin-Regulating Portfolio at the American Academy of Ophthalmology Annual Meeting
10/8/2019
AAO 2019 To Feature Multiple Presentations by Leading Experts on Allegro’s Dry Age-Related Macular Degeneration and Dry Eye Disease Assets
-
GenSight Biologics Appoints Magali Taiel as Chief Medical Officer
10/8/2019
GenSight Biologics announced the appointment of Magali Taiel, MD, as Chief Medical Officer, effective immediately.
-
Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update
10/7/2019
POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the third quarter and nine months ended September 30, 2019.
-
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
10/7/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-clinical data for its lead pipeline compound, SBT-272, at the 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium in Clearwater Beach, Fla.
-
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
10/1/2019
Stealth BioTherapeutics Corp announced that Reenie McCarthy, Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 5:20 p.m. ET in New York.